DALLAS, Dec. 14, 2005 (PRIMEZONE) -- StockGuru.com has issued a profile report on Chembio Diagnostics, Inc. (OTCBB:CEMI). The report is authored by Shailesh Dhuri, CFA and a Senior Financial Analyst for StockGuru.com. The report discusses the company's international marketing of its three rapid HIV tests as well as the company's veterinary TB tests.
Mr. Dhuri issues the following conclusion in the report:
"The need for rapid, accurate testing for infectious diseases cannot be underestimated. The unfortunate global spread of HIV infection and the resulting increase in TB and such other infectious incidence is a major cause of worry. However, this trend provides a growth opportunity for companies who are able to produce rapid test kits addressing this market."
To view the complete profile report authored by Shailesh Dhuri, please visit: http://www.stockguru.com/profiles/cemi/report.php
To view the StockGuru.com profile for Chembio Diagnostics, Inc., please visit: http://www.stockguru.com/profiles/cemi/index.php
In December, Stock Guru Publisher John Pentony interviewed Chembio Diagnostics' Lawrence Siebert. In the interview, Mr. Siebert gave a comprehensive update on the company and its efforts serving the global need for HIV testing.
To listen to the interview, please visit: http://www.stockguru.com/profiles/cemi/interview.php
ABOUT CHEMBIO
Chembio Diagnostics Inc. (Chembio) is a global leader in the development, research, manufacturing and marketing of rapid diagnostic tests for various infectious diseases, including HIV, human and veterinary TB, and Chagas Disease. Chembio Diagnostic Systems, Inc. is the 100%-owned subsidiary of Chembio Diagnostics, Inc. Additional information can be found at www.chembio.com.
About StockGuru.com
StockGuru.com features daily alerts going out three times daily to members. To join our email alert list, please visit: http://www.stockguru.com/stocks.htm
To feature your publicly traded company in our alerts, or to discuss our complete services, please contact: John Pentony at (469) 252-3031 or email publisher@stockguru.com. We offer a variety of services including profiling publicly traded companies on our web site, we do interviews with CEOs or other key executives on our web site, and we have our financial writers cover our companies.
FORWARD-LOOKING STATEMENTS
Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing and the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.
Disclosure: Pentony Enterprises LLC was compensated $9,000 for profile coverage. Pentony Enterprises LLC is not a registered investment adviser or broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.